Top-line results of Abrysvo vaccine for RSV in immunocompromised adults – Pfizer
Pfizer Inc. announced positive top-line safety and immunogenicity results from sub-study B of the ongoing pivotal Phase III clinical trial ( NCT05842967 ) MONeT (RSV I Mmunizati ONStudy… read more.